From the Division of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Department of Cardiology, Barts Heart Centre, London and Queen Mary University of London, London, UK.
Cardiol Rev. 2020 Jul/Aug;28(4):208-212. doi: 10.1097/CRD.0000000000000298.
Despite recent advances in drug-eluting stent (DES) technology, late adverse events remain concerns after percutaneous coronary intervention. The persistence of polymer material on DES has been suggested as a trigger for chronic inflammation. The Firehawk, a novel DES, has a unique design with recessed abluminal grooves, to which sirolimus and biodegradable polymer are applied. The Firehawk stent is designed to minimize polymer volume and antiproliferative drug concentration to reduce inflammation and hypersensitivity reactions. Several recent trials have reported the clinical outcomes of this device. This article provides a review of the current clinical evidence concerning the Firehawk stent.
尽管药物洗脱支架（DES）技术最近取得了进展，但经皮冠状动脉介入治疗后晚期不良事件仍然令人担忧。DES 上聚合物材料的存在被认为是慢性炎症的触发因素。Firehawk 是一种新型的 DES，具有独特的设计，包括向心侧凹槽，其中应用了西罗莫司和可生物降解聚合物。Firehawk 支架旨在最大限度地减少聚合物体积和抗增殖药物浓度，以减少炎症和超敏反应。最近的几项试验已经报道了该器械的临床结果。本文综述了 Firehawk 支架的现有临床证据。
